These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27069358)

  • 1. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.
    Rondanelli M; Perna S; Astrone P; Grugnetti A; Solerte SB; Guido D
    Patient Prefer Adherence; 2016; 10():407-13. PubMed ID: 27069358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.
    Perna S; Guido D; Bologna C; Solerte SB; Guerriero F; Isu A; Rondanelli M
    Aging Clin Exp Res; 2016 Dec; 28(6):1251-1257. PubMed ID: 26749118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visceral Adiposity Measurements, Metabolic and Inflammatory Profi le in Obese Patients with and Without Type 2 Diabetes Mellitus: A Crosssectional Analysis.
    Wanderley Rocha DR; Jorge AR; Braulio VB; Arbex AK; Marcadenti A
    Curr Diabetes Rev; 2017; 13(1):11-18. PubMed ID: 26467189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Krishnan G; Jothydev S
    Int J Gen Med; 2012; 5():317-22. PubMed ID: 22536087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series.
    Ishii S; Nagai Y; Sada Y; Fukuda H; Nakamura Y; Matsuba R; Nakagawa T; Kato H; Tanaka Y
    J Clin Med Res; 2019 Mar; 11(3):219-224. PubMed ID: 30834046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes.
    Ariel D; Kim SH; Abbasi F; Lamendola CA; Liu A; Reaven GM
    Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1317-22. PubMed ID: 25280957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.
    de Luis DA; Ovalle HF; Soto GD; Izaola O; de la Fuente B; Romero E
    J Investig Med; 2014 Feb; 62(2):324-7. PubMed ID: 24322329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus].
    Yu DN; Wang LJ; Cheng B; Li M; Pan Q; Guo LX
    Zhonghua Nei Ke Za Zhi; 2021 Nov; 60(11):982-986. PubMed ID: 34689519
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes.
    Boden G; Sargrad K; Homko C; Mozzoli M; Stein TP
    Ann Intern Med; 2005 Mar; 142(6):403-11. PubMed ID: 15767618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of body fat and improved lipid profile associated with daily consumption of a Puer tea extract in a hyperlipidemic population: a randomized placebo-controlled trial.
    Jensen GS; Beaman JL; He Y; Guo Z; Sun H
    Clin Interv Aging; 2016; 11():367-76. PubMed ID: 27069360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
    Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
    Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
    Tong PC; Lee ZS; Sea MM; Chow CC; Ko GT; Chan WB; So WY; Ma RC; Ozaki R; Woo J; Cockram CS; Chan JC
    Arch Intern Med; 2002 Nov; 162(21):2428-35. PubMed ID: 12437401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2020 Aug; 22(8):1417-1424. PubMed ID: 32250534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients].
    Zhang Y; Liu S; Fan C; Zeng Y; Li J; Xie C; Xue Y; Guan M
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Apr; 39(4):450-455. PubMed ID: 31068289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study.
    Pontiroli AE; Pizzocri P; Librenti MC; Vedani P; Marchi M; Cucchi E; Orena C; Paganelli M; Giacomelli M; Ferla G; Folli F
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3555-61. PubMed ID: 12161474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
    Rizzo M; Rizvi AA; Patti AM; Nikolic D; Giglio RV; Castellino G; Li Volti G; Caprio M; Montalto G; Provenzano V; Genovese S; Ceriello A
    Cardiovasc Diabetol; 2016 Dec; 15(1):162. PubMed ID: 27912784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.